60 Degrees Pharmaceuticals (SXTP) Debt to Equity (2022 - 2025)
60 Degrees Pharmaceuticals (SXTP) has disclosed Debt to Equity for 4 consecutive years, with $0.18 as the latest value for Q3 2025.
- On a quarterly basis, Debt to Equity rose 75.33% to $0.18 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.18, a 75.33% increase, with the full-year FY2024 number at $0.16, down 66.97% from a year prior.
- Debt to Equity was $0.18 for Q3 2025 at 60 Degrees Pharmaceuticals, down from $0.33 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.48 in Q4 2023 to a low of -$0.13 in Q2 2023.
- A 4-year average of $0.16 and a median of $0.16 in 2024 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: skyrocketed 697.19% in 2023, then tumbled 68.65% in 2024.
- 60 Degrees Pharmaceuticals' Debt to Equity stood at -$0.08 in 2022, then surged by 697.19% to $0.48 in 2023, then crashed by 66.97% to $0.16 in 2024, then grew by 15.5% to $0.18 in 2025.
- Per Business Quant, the three most recent readings for SXTP's Debt to Equity are $0.18 (Q3 2025), $0.33 (Q2 2025), and $0.16 (Q1 2025).